IMMUNO-ONCOLOGY INSIGHTS

Spotlights 2024

Assessing the evolving I-O landscape: key challenges and opportunities for 2024

View

Assessing the evolving I-O landscape: key challenges and opportunities for 2024

Progress being made in solid tumors
Are cancer vaccines back from the dead?
What’s next for checkpoints?
- What will the development of biosimilars mean for the field?
Investor, financial, and market access trends

View

Combination therapy development

Are multimodality approaches the future of the field?
With combination trials proving complex and expensive, how can resources best be deployed/ trial design be optimized?
Combinations in solid tumors—opportunities and challenges
Safety considerations: will synergistic effect also result in synergistic toxicity?

View

Solving the challenges of solid tumors

Translating successes in blood cancer into the solid tumor space
Understanding and addressing mechanisms of tumor resistance
Understanding and overcoming barriers posed by the TME

Translational insights: bridging the gap from preclinical R&D to the clinic

View

Translational insights: bridging the gap from preclinical R&D to the clinic

What is going wrong between preclinical in vitro/ in vivo settings and clinical in vivo settings?
What model systems can predict patient response to investigational molecules in practice?
How can current in vitro models be improved to better represent the complexity of the tumor, immune system, and surrounding tissue?
What lessons can be drawn from previous negative outcomes from preclinical studies?

View

Clinical development strategy

Clinical trial design innovation
Dose selection and optimization
Assessing the shifting regulatory landscape
How can the I-O community work to increase global patient access?
Increasing diversity and including the patient voice in clinical trial strategy and planning

Improving patient selection and stratification

View

Improving patient selection and stratification

Monitoring response and predicting outcome—how can different streams of data (pathology, ctDNA, radiology, etc.) be better harnessed and combined?
Novel biomarker discovery and development
Patient selection and precision medicine strategies
Improved methods of early detection and early detection of relapse

Addressing ongoing safety and toxicity issues

View

Addressing ongoing safety and toxicity issues

Achieving the greatest benefit with the least toxicity
How can we target tumor cells more accurately?
Most solid tumor antigens are not restricted—are
there subsets of targets that can be more specific?
Mechanisms of anti-tumor activity and toxicity in I-O
Does the field need to better manage toxicity with existing therapies, or find new targets and approaches?

View

Tools and trends of tomorrow

Exploring key enabling technology and platform innovation trends and advances for the year(s) to come